About Us
Science & Innovation
Products and Resources
Our Responsibility
Careers
Investors
Media

Press Releases
Featured News
Press Statements
Subscribe
Media Contacts
Social Media

Press Releases

Year Category Keywords

Advanced Search

Search

Search Headlines Only

Category

From

To

Asset Types

Video Audio Photos Documents Events Standard

Aug 2, 2005

Sanofi-aventis Issues Strong Support for Voluntary “Guiding Principles” on DTC Advertising
Jul 27, 2005

ALLEGRA-D® 24 HOUR (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) EXTENDED RELEASE TABLETS NOW AVAILABLE FOR SEASONAL ALLERGY SUFFERERS
Jul 19, 2005

Strong net sales growth in the first half of 2005: 11.0% on a comparable basis - Further increase in market share in the second quarter
Jun 30, 2005

Sports Legend Tony Gwynn Teams up with Former Baseball Champions to Raise Awareness of Deep-Vein Thrombosis (DVT) in the National Educational Campaign, "DVT Blood Clots: Know The Stats. Know Your Risk.”
Jun 28, 2005

PANEL OF EXPERTS AGREE THAT BONE MINERAL DENSITY IS NO LONGER ENOUGH
Jun 23, 2005

RIMONABANT ACCEPTED FOR FILING BY THE FDA
Jun 14, 2005

Data presented at American Diabetes Association Scientific Sessions support Exubera® Efficacy and Safety Profile in Type 1 and Type 2 Diabetes
Jun 13, 2005

Lantus® Add-on to Oral Monotherapy Therapy Showed Improved Glycemic Control in Type 2 Diabetes Patients Compared to Oral Actos Add-on to Oral Therapy
Jun 13, 2005

Clinical Study Results Demonstrated Greater Flexibility With Mealtime Dosing of Apidra® When Compared to Regular Human Insulin
Jun 13, 2005

DATA PRESENTED AT ADA SHOWED THAT BASAL INSULIN THERAPY WITH LANTUS® ACHIEVED TARGET GLYCEMIC CONTROL IN POORLY CONTROLLED TYPE 2 DIABETES
Jun 12, 2005

Rimonabant study shows significant improvements in HbA1c and cardiometabolic risk factors in people with type 2 diabetes
Jun 8, 2005

Prospective Study Published in Diabetes Care Confirms Basal Therapy with Lantus® Improves Glycemic Control in Patients with Type 2 Diabetes Poorly Controlled on Prior Insulin Regimens
Jun 2, 2005

Landmark Taxotere® Study in Early Stage Breast Cancer Published in the New England Journal of Medicine
May 31, 2005

Sanofi-aventis Annual General Meeting
May 25, 2005

UROXATRAL® (alfuzosin HCl) STUDY SHOWS IMPROVEMENT UP TO TWO YEARS IN LOWER URINARY TRACT SYMPTOMS AND SEXUAL FUNCTION IN MEN WITH ENLARGED PROSTATES
May 24, 2005

New Study Demonstrates Clinical Efficacy of Telithromycin Superior to Standard First-Line Antibiotic Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia (CAP)
May 23, 2005

New Data Demonstrate Alvesco® (ciclesonide) Significantly Reduces Oral Corticosteroid Use in Patients with Severe, Persistent Asthma
May 15, 2005

Taxotere® Regimen Demonstrates Significant Survival Benefit In The Treatment Of Advanced Gastric Cancer
May 13, 2005

Sanofi-aventis 2005 first-quarter net sales
May 10, 2005

Rescheduling of the pre-trial order date in the United States Plavix® litigation
May 10, 2005

New Eloxatin® and Taxotere® research to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO)
Apr 15, 2005

Sanofi-aventis affirms its commitment to Access to Medicines in the "Southern countries", with a policy of tiered drug prices geared to populations incomes
Apr 11, 2005

FDA issues approvable letter for AMBIEN CR™ (zolpidem tartrate extended release) C IV for the treatment of Insomnia
Apr 7, 2005

Sanofi-aventis Statement
Apr 1, 2005

Sanofi-aventis concludes €10 billion in medium-term credit agreements with its banks to refinance the Aventis acquisition financing entered into in April 2004
Mar 30, 2005

Rescheduling of the pre-trial order date in the United States Plavix® litigation
Mar 24, 2005

Sanofi-aventis joins the fight against tuberculosis in South Africa
Mar 22, 2005

New Data Demonstrate Alvesco® (ciclesonide) Has a Low Incidence of Mouth- and Throat- Related Side Effects in Pediatric Asthma Patients
Mar 22, 2005

New Data Demonstrate Alvesco® (ciclesonide) Significantly Improves Quality-of-Life for Patients with Mild-to-Moderate Asthma
Mar 22, 2005

Court grants Sanofi-aventis's request for Order of Prohibition in the Canadian Plavix® litigation
Mar 11, 2005

SANOFI-AVENTIS SUES NOVOPHARM FOR PATENT INFRINGEMENT IN CANADA
Mar 9, 2005

CLOPIDOGREL IMPROVED CORONARY PERFUSION AND REDUCED MORTALITY IN ACUTE HEART ATTACK
Mar 2, 2005

PFIZER AND THE SANOFI-AVENTIS GROUP SEEK APPROVAL TO MARKET EXUBERA® IN THE UNITED STATES
Mar 1, 2005

Sanofi-aventis 2004 Results
Feb 24, 2005

Creation of the sanofi-aventis European Works Council
Feb 24, 2005

First Pilot Study to Show Benefit Using Hyalgan® (sodium hyaluronate) in the Treatment of Osteoarthritis of the Ankle
Feb 23, 2005

Update of the Patent Litigation Schedule in the United States for Plavix®
Feb 18, 2005

Sanofi-aventis world solidarity day on behalf of South East Asia - January 25, 2005: "Sharing in solidarity"
Feb 17, 2005

Sanofi-aventis announces commercial availability of twice-yearly Eligard®
Feb 2, 2005

Sanofi-aventis receives FDA approval for new Eloxatin™ formulation
Jan 26, 2005

2004 pro forma combined net sales: up 10.0% on a comparable basis
Jan 25, 2005

Plavix® patent
Jan 25, 2005

Sanofi-aventis “Solidarity Day” offers additional aid, assistance to Southeast Asia “Sharing in solidarity”
Jan 19, 2005

The European Commission imposes a fine on certain MCAA producers
Jan 11, 2005

Taxotere® (docetaxel) receives 2 new European approvals for treatment of breast cancer
Jan 11, 2005

New Together Rx Access™ Card offers Americans with no prescription drug coverage savings at the pharmacy counter
Jan 10, 2005

Sanofi-aventis and Regeneron Pharmaceuticals reaffirm development commitment
Jan 10, 2005

Aventis Pasteur, the vaccine division of the sanofi-aventis Group, changes its name to sanofi Pasteur
Jan 6, 2005

Update of the patent litigation schedule in the United States for Plavix®
Jan 3, 2005

Sanofi-aventis provides Humanitarian Aid for South-East Asia

Show 5 10 25 50 100 per page

«
1
…
9
10
11
12
13
14
15
16
17
»

Print
Email page
RSS

Follow Us

Contact
Sitemap
Legal Notice

© 2005-2021 sanofi-aventis U.S. LLC - All rights reserved